UroGen Q1 Jelmyto revenue $13.6M (+81% YoY); net loss $28.4M; cash $137.1M

UroGen Pharma Ltd.

Jelmyto net revenue $13.6M, +81% vs Q1 2021 ($7.5M).
Net loss $28.4M ($1.25/shr) vs $25.9M ($1.17/shr) a year ago.
Cash, cash equivalents & marketable securities $137.1M at Mar 31, up from $89.8M.
Reiterated FY2022 Jelmyto revenue guidance $70-80M and operating expenses $140-160M.
Phase 3 ENVISION trial of UGN-102 enrollment expected to complete by end 2022; NDA submission projected 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.